View clinical trials related to Healthy Volunteers.
Filter by:Previous studies have already revealed the involvement of the serotoninergic system in the social behavior process. For example, more serotonin (5HT) was found in dominant male adult monkeys. Little is known about the serotoninergic implication in human's social behavior. The project aims to clarify the role of the serotoninergic system in social behavior in relation to the process of social hierarchical information. In order to determine how serotoninergic system is involved, the investigator will use a new technic TEP-fMRI. This technic allows us to measure the brain activity and the serotoninergic transporter occupancy (using the [C11]-DASB) at the same time. The current study aims to investigate whether serotonin transporter (5-HTT) activity correlates with the neural response (BOLD) during the detection of social dominance in facial expressions or other measures of social information processing. Blood sample, SLC6A4 (allele coding for the 5HT transporter) genotyping and neuropsychological questionnaires will give at the investigator more information and allow to investigate whether performance on social information processing is modulated by personality trait and genotype.
Enterotoxigenic Escherichia coli (ETEC) is a major cause of diarrhea worldwide. Vaccines and therapeutics are under development to prevent ETEC disease in children and travelers. One approach is to use passive protection (antibodies) to prevent infection. The purpose of this study are to assess the safety of serum-derived bovine immunoglobulins in healthy adult subjects when orally administered and to estimate protective efficacy of those preparations against moderate-severe diarrhea upon challenge with the ETEC strain B7A.
This is a randomized, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of Risdiplam in healthy Japanese participants.
SLC6A14 may serve as a biomarker for cervical dysplasia or cervical cancer.
The purpose of this study is to evaluate descriptively the long-term immunogenicity of at least 1 NoV vaccine administration.
The purpose of this study is to determine whether a web-based training program with text-based information as well as practical exercises can improve cross-cultural competencies in therapists.
Background: Arginine vasopressin (AVP) is a hormone made in the body. It can make negative feelings stronger. The way AVP is regulated may be abnormal in people who have mood and anxiety disorders. SRX246 is a new drug that can block a receptor for AVP on brain cells. Researchers want to study how this drug affects the way people respond to threat and anxiety. Objectives: To see if the new drug SRX246 affects how people respond to the threat of an unpleasant shock. Eligibility: Healthy adults ages 21-50 Design: Participants will be screened in another protocol. Participants will have 4 visits over 4 weeks. At visit 1, participants will have small electrodes taped to their arm to give shocks. Electrodes on the arm, chest, and face will measure sweat, heart rate, and blinking. Participants will hear loud noises and get test shocks for about 15 minutes. At the other 3 visits, participants will have some or all of these tests: - Blood and urine tests - Heart tests - Suicide screen At each visit, participants will answer questions about their mood and anxiety. They will identify emotions in pictures. They will have shock testing for 40 minutes: they will hear loud sounds through headphones and get shocks. Participants will take the study pill 2 times a day for a week after visit 1 and a week after visit 3. One week it will be SRX246. The other week it will be a placebo. Participants may be contacted daily to remind them to take the medicine. Participants will have either a follow-up visit or follow-up phone call.
Purpose: To evaluate the acute and chronic effects of a botanical supplement on strength, muscle function, and lean body mass Participants: The acute phase will include 30 participants, and the chronic phase will include 84 participants. All participants must be healthy recreationally active males between the ages of 18 and 35 years. Procedures (methods): Acute phase: Participants will complete three testing visits as part of as part of a cross-over design, during which strength and muscle function will be assessed prior to and following consumption of a supplement. The experimental supplement is a blend of the botanical extracts; treatment arms will include a full dose (FULL; 350 mg capsule), half dose (HALF; 175 mg plus maltodextrin), or placebo (PLA; maltodextrin). Chronic phase: Body composition, muscle cross-sectional area, a complete blood count and metabolic panel, subjective surveys, and strength will be measured prior to and following an 8-week supervised resistance training program, in conjunction with daily supplementation of FULL, HALF, or PLA.
This study determines the effects of posture on time up and go test. Half of the subjects will assume a high-power posture, while the other half will assume a low-power posture.
The purpose of the study is to investigate the drug octreotide acetate in a new intranasal formulation and compare it to the FDA-approved subcutaneous (SC) injection formulation. The two octreotide acetate formulations will be evaluated following separate administrations for safety and tolerability including any side effects, the speed at which the drug is absorbed and eliminated in the body, and the ability of the drug to lower the levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1).